Recombinant Vaccine–Derived Poliovirus in Madagascar
2003

Recombinant Vaccine-Derived Poliovirus in Madagascar

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): Rousset Dominique, Rakoto-Andrianarivelo Mala, Razafindratsimandresy Richter, Randriamanalina Bakolalalo, Guillot Sophie, Balanant Jean, Mauclère Philippe, Delpeyroux Francis

Primary Institution: Institut Pasteur de Madagascar

Hypothesis

The study investigates the occurrence and characteristics of vaccine-derived poliovirus (VDPV) in Madagascar.

Conclusion

The study found that the detected VDPVs were likely the result of recombination between oral polio vaccine strains and nonpolio enteroviruses.

Supporting Evidence

  • Five cases of acute flaccid paralysis associated with VDPV type 2 were reported.
  • Nine type 2 poliovirus strains were isolated and characterized.
  • The RFLP profiles indicated recombination with other enteroviruses.
  • Partial genomic sequencing showed differences from the type 2 OPV strain.
  • No wild poliovirus strains have been isolated in Madagascar since 1997.

Takeaway

Some kids in Madagascar got sick from a type of polio virus that came from a vaccine, not from the wild virus. This shows that vaccines can sometimes mix with other viruses.

Methodology

The study used restriction fragment length polymorphism (RFLP) assays and genomic sequencing to analyze poliovirus isolates.

Limitations

The study cannot exclude the possibility that wild polioviruses were imported or circulating silently.

Participant Demographics

The cases involved children aged 6 months to 14 years from both urban and rural areas.

Digital Object Identifier (DOI)

10.3201/eid0907.020692

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication